Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISES: Sunitinib and Everolimus Rotation vs Sequence in mRCC
NCT01784978Phase 2Terminated
- Sponsor
- Associació Per la Recerca Oncològica
- Start
- Feb 2013
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of everolimus in metastatic renal cell carcinoma (mRCC), sponsored by Associació Per la Recerca Oncològica. Started Feb 2013; status: terminated.
02
Drugs
everolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01784978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01784978.